A multicenter, phase I/IIA, open-label, dose-escalation study to determine the maximum tolerated dose and to evaluate the safety profile of CC-4047 [pomalidomide] administered in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.

Trial Profile

A multicenter, phase I/IIA, open-label, dose-escalation study to determine the maximum tolerated dose and to evaluate the safety profile of CC-4047 [pomalidomide] administered in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Pomalidomide (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 16 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 May 2011 Actual End Date added to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top